https://doi.org/10.4081/btvb.2023.60
How to manage antithrombotic treatments in thrombocytopenic patients with cancer. Comments on the European Haematology Association guidelines
Submitted: 11 November 2022
Accepted: 7 December 2022
Published: 27 January 2023
Accepted: 7 December 2022
Abstract Views: 550
PDF: 259
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
With ageing of the population, both the risks of cardiovascular disease (CVD) and cancer are increasing worldwide, and the risk factors (e.g. obesity, diabetes) are often shared between the two conditions. Thus, more subjects will also develop the two illnesses concurrently [...].
Willems RAL, Winckers K, Biesmans C, et al. Evolving data on cardiovascular complications in cancer. Thromb Res 2022;213:S87-S94.
DOI: https://doi.org/10.1016/j.thromres.2022.01.003
Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist 2017;22:199-2.
DOI: https://doi.org/10.1634/theoncologist.2016-0214
Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017;70:926-38.
DOI: https://doi.org/10.1016/j.jacc.2017.06.047
Navi BB, Reiner AS, Kamel H, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 2019;133:781-9.
DOI: https://doi.org/10.1182/blood-2018-06-860874
Falanga A, Leader A, Ambaglio C, et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. HemaSphere 2022;6:e750.
DOI: https://doi.org/10.1097/HS9.0000000000000750
How to Cite
Falanga, A., Ten Cate, H., & Rocca, B. (2023). How to manage antithrombotic treatments in thrombocytopenic patients with cancer. Comments on the European Haematology Association guidelines. Bleeding, Thrombosis and Vascular Biology, 2(1). https://doi.org/10.4081/btvb.2023.60
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Most read articles by the same author(s)
- Daniela Poli, Walter Ageno, Emilia Antonucci, Salvatore Bradamante, Eugenio Bucherini, Paolo Chiarugi, Antonio Chistolini, Benilde Cosmi, Anna Falanga, Antonio Insana, Domenico Lione, Rosa Maria Lombardi, Giuseppe Malcangi, Rossella Marcucci, Giuliana Martini, Lucilla Masciocco, Carmelo Paparo, Daniele Pastori, Simona Pedrini, Vittorio Pengo, Pasquale Pignatelli, Andrea Toma, Sophie Testa, Gualtiero Palareti, Management of anticoagulation in atrial fibrillation patients in Italy: insight from the Atrial Fibrillation-Survey on Anticoagulated Patients Register (AF-START) , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Luca Barcella, Chiara Ambaglio, Paolo Gritti, Francesca Schieppati, Varusca Brusegan, Eleonora Sanga, Marina Marchetti, Luca Lorini, Anna Falanga, Long-term persistence of high anti-PF4 antibodies titer in a challenging case of AZD1222 vaccine-induced thrombotic thrombocytopenia , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
Similar Articles
- Guest Editors: Anna Falanga, Benjamin Brenner, Alok A. Khorana, Oral Communications and Posters , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024): 12th ICTHIC
- Paola Binetti, Thrombotic thrombocytopenic purpura: much done, but still a lot to do , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Stefano Lancellotti, Monica Sacco, Maira Tardugno, Antonietta Ferretti, Raimondo De Cristofaro, The Von Willebrand factor-ADAMTS-13 axis: a two-faced Janus in bleeding and thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- Paolo Prandoni, Personalized bleeding risk assessment for atrial fibrillation patients on direct oral anticoagulants: the DOAC score , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Pier Mannuccio Mannucci, Growing weapons to fight hemophilia , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Gaetano Torlone, The metaphor of Ukrainian science “bleeding” , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Luca D'Ambrosio, Maurizio Forte, Giacomo Frati, Sebastiano Sciarretta, Role of platelet autophagy in cardiovascular diseases , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Rossella Marcucci, Rosanna Abbate, What is the gender of thrombosis? A natural model of precision medicine , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Giovanni Tiscia, Elvira Grandone, Talking about assisted reproductive techniques and thromboembolic risk: everything we always wanted to know , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
- Tiziano Barbui, Clonal hematopoiesis and inflammation: a link with thrombosis and malignancy , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 2 (2022)
You may also start an advanced similarity search for this article.
